Table 1 Demographic data and laboratory investigations among the studied patients (N = 91)
From: Role of GSDMD and VEGF in differentiating between malignant and non-malignant pleural effusions
Studied variables | Malignant pleural effusion group (MPE) (N = 23) | Tuberculous pleural effusion (TBPE) (N = 8) | Para-infectious PIPE (N = 24) | transudative pleural effusion group (TPE) (N = 36) |
|---|---|---|---|---|
Age (years) Mean ± SD Median Range | 48.3 ± 13.6 47.0 28.0 – 71.0 | 37.8 ± 12.0 39.0 19.0 – 58.0 | 42.2 ± 11.5 40.5 23.0 – 68.0 | 47.8 ± 10.7 44.0 33.0 – 69.0 |
Sex Male Female | 15(65.2) 8(34.8) | 5(62.5) 3(37.5) | 16(66.7) 8(33.3) | 18(50.0) 18(50.0) |
Pleural Effusion total protein gm/dl Mean ± SD Median Range | 6.62 ± 1.21 6.40 4.20 – 8.97 | 5.63 ± 0.90 5.56 4.28 – 6.96 | 5.48 ± 1.27 5.18 3.48 – 8.20 | 2.03 ± 0.73 2.10 0.40 – 3.38 |
Pleural Effusion LDH (IU/L) Mean ± SD Median Range | 652.0 ± 192.1 573.3 357.8– 988.0 | 503.3 ± 144.9 469.1 302.0 – 768.0 | 516.2 ± 248.8 420.7 282.5 – 1100 | 98.8 ± 28.2 95.0 59.7 – 187.0 |
ADA (IU/L) Mean ± SD Median Range | 36.6 ± 9.94 37.5 11.0 – 55.0 | 76.3 ± 24.6 72.0 49.0 – 128.0 | 21.2 ± 7.52 21.0 4.90 – 35.0 | 7.72 ± 1.46 8.00 4.30 – 10.0 |
Total leucocytic cells/mm3 < 1000 > 1000 | 9(39.1) 14(60.9) | 4(50.0) 4(50.0) | 11(45.8) 13(54.2) | 36(100.0) 0(0.00) |
Differential cell count eosinophilic lymphocytic neutrophil polymorphs | 2(8.70) 21(91.3) 0(0.00) 0(0.00) | 0(0.00) 8(100) 0(0.00) 0(0.00) | 0(0.00) 4(16.7) 0(0.00) 0(0.00) | 1(2.80) 30(83.3) 1(2.80) 4(11.1) |
Type of malignancy in MPE Bronchogenic carcinoma Breast cancer Mesothelioma Lymphoma Hepatocellular carcinoma Ovarian carcinoma | 7(30.4) 5(21.7) 3(13.1) 4(17.4) 3(13.1) 1(4.3) | - | - | - |